CTOs on the Move

Specific Diagnostics

www.specific.com

 
Bloodstream infection leading to sepsis is responsible for more than half of all deaths in hospitals and is the most expensive condition treated in hospitals. Mortality rate increases 6% every hour from onset. Therefore, it is critical the right antibiotic treatment is determined quickly. Current methodologies require 3 days to determine the effective antibiotic. Specific Diagnostics has developed a new technology that determines the effective antibiotic in less than 1 day. Specific`s Reveal™ instrument and assay are cost effective and labor-saving allowing clinics to readily deploy the Specific Reveal solution. Specific`s unique patented technology leverages a low-cost small molecule sensor ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Medrecon

Medrecon is a Garwood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IOMED

IOMED is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

J and B Medical Supply

J and B Medical Supply, Inc. is a Wixom, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Antares Pharma

Antares Pharma is a revenue-generating product focused specialty pharmaceutical company that has developed three proprietary platforms, two of which now include FDA approved products. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. We focus on self-injection pharmaceutical products and technologies and topical gel -based products. Our subcutaneous injection technology platforms include Vibex™ disposable pressure-assisted auto injectors, Vision® reusable needle-free injectors, and disposable multi-use pen injectors.

Neuromod Devices

Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation. We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control of their own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle. Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as ringing in the ears​.